Leaning into the immune system’s complexity
By designing new tools that can analyze huge libraries of immune cells and their targets, Michael Birnbaum hopes to generate better T cell therapies for cancer and other diseases.
By designing new tools that can analyze huge libraries of immune cells and their targets, Michael Birnbaum hopes to generate better T cell therapies for cancer and other diseases.
Leuko, founded by a research team at MIT, is giving doctors a noninvasive way to monitor cancer patients’ health during chemotherapy — no blood tests needed.
By capturing short-lived RNA molecules, scientists can map relationships between genes and the regulatory elements that control them.
An atlas of human protein kinases enables scientists to map cell signaling pathways with unprecedented speed and detail.
Senior Hanjun Lee planned to pursue chemistry at MIT. A course in genetics changed that.
Ashutosh Kumar, a materials science and engineering PhD student and MathWorks Fellow, applies his eclectic skills to studying the relationship between bacteria and cancer.
New CLAUDIA system could continuously monitor patients during an infusion and adjust dosage to maintain optimal drug levels.
Immunai’s founders were researchers at MIT when they launched their company to help predict how patients will respond to new treatments.
In MIT’s 2024 Killian Lecture, chemical engineer Paula Hammond described her groundbreaking work on nanoparticles designed to attack tumor cells.
MIT spinout Strand Therapeutics has developed a new class of mRNA molecules that can sense where they are in the body, for more targeted and powerful treatments.
Joining three teams backed by a total of $75 million, MIT researchers will tackle some of cancer’s toughest challenges.
With the new technique, MIT researchers hope to identify mutations that could be targeted with new cancer therapies.
The technology could offer a cheap, fast way to test for PFAS, which have been linked to cancer and other health problems.
Stimulating gamma brain waves may protect cancer patients from memory impairment and other cognitive effects of chemotherapy.
A new study finds precancerous colon cells turn on a gene called SOX17, which helps them evade detection and develop into more advanced tumors.